Laura Dillon, PhD, FACMG

Research Associate Professor and Medical Geneticist at Virginia Tech FBRI Cancer Research Center in DC @FralinBiomed @virginia_tech | ❤️🧬 | comments my own

[Laura Dillon, PhD, FACMG @LauraWDillon]

@JackYGhannam @NatureCancer Congrats Jack!!

[Chris Hourigan @DrChrisHourigan]

Genomics of Acute Myeloid Leukemia at Diagnosis and Remission
https://t.co/7xURj6vHKf

[Chris Hourigan @DrChrisHourigan]

Important talk at #ASH25 by @JesseTettero on AML MRD as a surrogate endpoint (Session 619 - Valencia Room W415A).

[Chris Hourigan @DrChrisHourigan]

Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at #ASH25 #ASH2025 - the largest cohort of paired tumor and remission WGS from patients with AML https://t.co/2WozDIrEtA

[Chris Hourigan @DrChrisHourigan]

#Tandem25 I'll be talking today (10.30am Ballroom B, 4th flr) about the Pre-MEASURE AML MRD project which used CIBMTR Clinical Data and Biospecimens. The current issue of https://t.co/fH8hzeOCnu focuses on this research, and is dedicated to Dr. Kristin Page our @CIBMTR colleague and co-author. https://t.co/VlAl8fZ8r7 . .
If you have not yet, please consider donating here: https://t.co/trYAIx0aCG

[Chris Hourigan @DrChrisHourigan]

Delighted to have Dr. Dillon join us at the Virginia Tech @FralinBiomed Cancer Research Center in DC as Research Associate Professor. The Pre-MEASURE team is back together(!) as we, with help from others, dive into the MEASURE protocol and continue our @FNIH_Org work on AML MRD

[Laura Dillon, PhD, FACMG @LauraWDillon]

New Year, new job, a fresh start. After almost 8 years of service at the NIH I am excited to be starting this year off joining @DrChrisHourigan at the @virginia_tech @FralinBiomed Cancer Research Center in Washington, DC. Exciting things to come.

[Chris Hourigan @DrChrisHourigan]

TP53 mutation screening for patients at risk of myeloid malignancy | Leukemia ⁦@Devdeep07⁩ ⁦⁦⁦@LauraWDillon⁩ https://t.co/NgjduYvHoT

[Anand Patel @Anand_88_Patel]

Excellent new paper in @JAMAOnc by @LauraWDillon @DrChrisHourigan et al on FLT3-ITD MRD prior to allo-HCT in AML!

The amount of MRD matters!

https://t.co/NzruXUbTvD

[Chris Hourigan @DrChrisHourigan]

https://t.co/MmjMLoUBcB

[ESH (Haematology) @ESHaematology]

#ESHAL2024 @JordiEsteve17 chairs a very entertaining - and not entirely serious - debate discussing whether AML MRD conversion before alloSCT has to be achieved. @DrChrisHourigan is PRO; @charliecraddock is CON: Stay tuned, debate soon available on #ESHELEARNING
#ESHCONFERENCES

[Chris Hourigan @DrChrisHourigan]

Secondary primary malignancies are increasingly recognized as a risk of cellular therapies (esp. MDS/AML, also after chemotx/radiotx) - we were asked to bring up a ultra-deep NGS assay for DISCOVERY of TP53 mutations for screening prior to treatment https://t.co/GQUcfLnRN4

[Laura Dillon, PhD, FACMG @LauraWDillon]

@KatieLaiMD_MPH @dralainmina @theNCI @DrChrisHourigan Was great catching up and hearing about all your exciting work!

[Laura Dillon, PhD, FACMG @LauraWDillon]

@DrChrisHourigan @KatieLindblad1 @IcahnMountSinai @HongYuenWong @VUMCDiscoveries Congrats Katie!!! So proud of you!

[Laura Dillon, PhD, FACMG @LauraWDillon]

@DrChrisHourigan Sorry I couldn’t be there in person at #ASH23 but happy to answer any questions! Happy to share this important data which provides insight for interpreting FLT3-ITD MRD information with important implications for clinical practice.

[Chris Hourigan @DrChrisHourigan]

Bottom lines: There does appear to be an association between level of FLT3-ITD persistence and clinical outcome (first time this has been definitively shown for AML MRD as far as I know). Levis and colleagues have found the same thing (they have an oral presentation later today)

[Chris Hourigan @DrChrisHourigan]

I encourage you to listen to the recorded poster presentation by @LauraWDillon (who is unable to attend ASH in person this year - due to another project she is working on)

[Chris Hourigan @DrChrisHourigan]

Cleveland clinic medical student ⁦@ClevelandClinic⁩ ⁦@hegdepranay1⁩ presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at ⁦@TheBethesdaLabs⁩ ⁦@NIH⁩ ⁦@CIBMTR⁩

[Chris Hourigan @DrChrisHourigan]

She crushed it! First major international talk for ⁦@GegeGui0⁩ - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. ⁦@TheBethesdaLabs⁩ ⁦@CIBMTR⁩ ⁦@ASH_hematology⁩

[Chris Hourigan @DrChrisHourigan]

Come listen (and support) Gege as she gives her first talk at an international hematology meeting! If we are serious about making things better for patients with blood cancer we need to encourage best and brightest students from other disciplines to work on our hardest problems